[ad_1]
Al Marsad Journal – Agencies: Clinical trials have shown that an anti-inflammatory drug called “colchicine” is effective in treating patients with Covid-19 and reducing the risk of complications from the disease, researchers in Canada say.
A great scientific discovery
The Montreal Heart Institute said in a statement Friday evening that the results of this study are a “great scientific revelation” and make colchicine, which is used to treat gout, “the first drug taken by way of oral to the world that can be used. to treat Covid-19 patients outside of hospitals. “
The statement added that the study results showed that colchicine reduced the risk of death or the need for hospitalization by 21 percent in Covid-19 patients compared to those who participated in the trials and received a placebo.
Conduct of studies
The study was conducted in Canada, the United States, Europe and South America on 4,488 patients.
In 4,159 participants who tested positive for Covid-19 using the “BCR” test, colchicine use reduced the need for hospitalization by 25%, reduced the need for artificial respiration by 50% and reduced deaths by 44%.
Collection is efficient
“Colchicine is effective in preventing dangerous inflammatory syndromes called ‘cytokine storms’, as well as in reducing complications associated with Covid-19, said the director of the Research Center of the Institut de Montreal and principal investigator of this study .
He added that the use of the drug “can have a significant impact on public health and the possibility of preventing complications of Covid-19 in millions of patients.”
The study was conducted on Covid-19 patients who were not hospitalized at the time of enrollment to participate in the trials and had at least one risk factor for complications.
Source link
